空气污染,新兴化学物质暴露和系统性红斑狼:一项超流行病学研究
Yaling Xu1, Hejing Pan1, Wu Chen1
1College of Basic Medical Science, Zhejiang Chinese Medical University, Hangzhou, China.
Frontiers in immunology
|November 3, 2025
概括
暴露于PM2.5和NO2空气污染物与系统性红斑狼 (SLE) 风险的增加有关. 需要对臭氧,PFAS和BP与SLE相关的进一步研究.
科学领域:
- 环境健康科学 环境健康科学
- 类风湿病学 类风湿病学
- 毒理学 毒理学 毒理学
背景情况:
- 系统性红斑狼 (SLE) 是一种具有复杂病因的慢性自身免疫性疾病.
- 环境因素,包括空气污染和化学物质暴露,越来越多地与SLE病原体有关.
- 了解这些关联对于公共卫生干预和疾病预防至关重要.
研究的目的:
- 评估空气污染,新兴化学污染物和SLE发病率之间的关联.
- 通过元分析,通过污染物类型澄清这些关系的方向和强度.
主要方法:
- 在PubMed和EMBASE数据库上进行了系统的文献搜索,直到2024年8月.
- 包括的观察性研究使用纽卡斯尔-太华尺度进行了质量评估.
- 用STATA进行了元分析,通过漏斗图和埃格尔测试评估了出版偏差.
主要成果:
- 分析了8项涉及超过130万个人的研究.
- 在SLE发病率和暴露于PM2.5 (OR=1.16),NO2 (OR=1.24) 和PFAS (OR=2.47) 之间发现了显著的积极关联.
- 臭氧 (O3) 显示出负相关性 (OR=0.83),而PM10,SO2和BP没有显示出显著的联系.
结论:
- PM2.5和NO2是SLE的潜在环境风险因素.
- 与O3的负面关联需要进一步调查; PFAS的关联需要更多证据.
- 减少对PM2.5和NO2的暴露可能会降低SLE风险,需要更严格的环境法规.
更多相关视频
09:33Visualizing Field Data Collection Procedures of Exposure and Biomarker Assessments for the Household Air Pollution Intervention Network Trial in India
Published on: December 23, 2022
2.6K
08:48Analysis of the Ambient Particulate Matter-induced Chromosomal Aberrations Using an In Vitro System
Published on: December 21, 2016
9.1K
相关概念视频
Types of Toxins
3.1K
Humans continually engage with an environment rich in potentially harmful chemicals. These are introduced to our bodies through inhalation, ingestion, or skin contact. These chemicals exist in various forms, such as air and environmental pollutants, agricultural chemicals, organic solvents, and heavy metals.
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
Air pollutants, primarily gases, pose significant threats to respiratory health, leading to conditions like hypoxia, lung cancer, and in extreme cases, death.
Environmental pollutants like...
3.1K
Toxic Reactions: Overview
1.8K
When toxic substances penetrate the human body, they disseminate to various tissues, undergoing metabolic changes. This process yields reactive metabolites that may covalently bind with specific target molecules, resulting in toxicity.
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
Toxicity falls into two primary categories: local and systemic.
Local toxicity appears at the exposure site, such as protein denaturation caused by caustic substances.
In contrast, systemic toxicity requires the toxic agent's absorption and distribution,...
1.8K
Asthma-I: Introduction
3.3K
Asthma is a chronic respiratory ailment that requires careful management due to its varying symptoms and influencing factors. It is characterized by airway inflammation, bronchial hyperresponsiveness, and reversible airflow obstruction, leading to symptoms like wheezing, shortness of breath, chest tightness, and coughing. The symptom frequency and intensity may vary considerably over time. It is also linked to immune system responses to allergens and irritants, highlighting the complex...
3.3K
Chronic Obstructive Pulmonary Disease-II: Pathophysiology
4.2K
Chronic Obstructive Pulmonary Disease (COPD) pathophysiology is intricate and multifaceted, involving a complex interplay of physiological processes. Understanding these mechanisms is crucial for effectively managing and treating COPD. Here is an in-depth look at the critical elements in the pathophysiology of COPD:
Chronic Inflammation
Chronic Inflammation
4.2K
Chronic Obstructive Pulmonary Disease-I: Introduction
3.5K
Chronic Obstructive Pulmonary Disease (COPD) is a long-lasting respiratory condition requiring continuous attention and care. It is a progressive lung disease that leads to breathing challenges due to airflow obstruction. It manifests as persistent respiratory symptoms and restricted airflow resulting from abnormalities in the airways and alveoli, usually due to long-term exposure to harmful particles or gases. COPD mainly consists of two primary conditions: emphysema and chronic bronchitis.
3.5K
Antiasthma Drugs: Leukotriene Modifiers
1.7K
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
1.7K
